Teacher Retirement System of Texas Purchases 1,505 Shares of Arcellx, Inc. (NASDAQ:ACLX)

Teacher Retirement System of Texas lifted its position in Arcellx, Inc. (NASDAQ:ACLX) by 18.7% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 9,556 shares of the company’s stock after purchasing an additional 1,505 shares during the quarter. Teacher Retirement System of Texas’ holdings in Arcellx were worth $733,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Janus Henderson Group PLC raised its stake in Arcellx by 5.7% in the third quarter. Janus Henderson Group PLC now owns 2,011,950 shares of the company’s stock valued at $168,026,000 after purchasing an additional 109,332 shares in the last quarter. RA Capital Management L.P. lifted its holdings in shares of Arcellx by 15.4% during the 3rd quarter. RA Capital Management L.P. now owns 1,851,479 shares of the company’s stock worth $154,617,000 after acquiring an additional 247,465 shares during the last quarter. Geode Capital Management LLC grew its position in Arcellx by 4.3% in the third quarter. Geode Capital Management LLC now owns 974,967 shares of the company’s stock worth $81,434,000 after acquiring an additional 39,781 shares in the last quarter. Lord Abbett & CO. LLC increased its stake in Arcellx by 2.1% in the third quarter. Lord Abbett & CO. LLC now owns 891,848 shares of the company’s stock valued at $74,478,000 after acquiring an additional 18,004 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in Arcellx by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 343,085 shares of the company’s stock valued at $26,311,000 after purchasing an additional 14,992 shares in the last quarter. Hedge funds and other institutional investors own 96.03% of the company’s stock.

Arcellx Stock Down 0.8 %

Shares of Arcellx stock opened at $67.96 on Monday. The firm has a market cap of $3.73 billion, a PE ratio of -95.72 and a beta of 0.32. The company’s fifty day simple moving average is $66.93 and its two-hundred day simple moving average is $77.72. Arcellx, Inc. has a 12-month low of $47.88 and a 12-month high of $107.37.

Arcellx (NASDAQ:ACLX) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.24). The business had revenue of $15.27 million for the quarter, compared to analysts’ expectations of $27.42 million. Arcellx had a negative net margin of 25.94% and a negative return on equity of 8.28%. As a group, sell-side analysts expect that Arcellx, Inc. will post -1.58 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Kavita Patel sold 1,500 shares of the firm’s stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $64.57, for a total value of $96,855.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Christopher Heery sold 3,301 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $79.55, for a total transaction of $262,594.55. Following the transaction, the insider now owns 35,517 shares in the company, valued at $2,825,377.35. This represents a 8.50 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 64,370 shares of company stock valued at $4,181,646. Company insiders own 6.24% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on ACLX. HC Wainwright reiterated a “buy” rating and issued a $115.00 price objective on shares of Arcellx in a report on Tuesday, December 10th. UBS Group boosted their target price on Arcellx from $106.00 to $114.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $105.00 price target on shares of Arcellx in a research report on Monday, December 9th. Thirteen research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $108.46.

About Arcellx

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).